MYDRIACYL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Feb 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MYDRIACYL by Alcon is clinical pharmacology this anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). First approved in 1960.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDRIACYL is an anticholinergic ophthalmic solution that blocks cholinergic responses in the iris sphincter and ciliary muscle, producing mydriasis (pupil dilation) and, at higher concentrations, cycloplegia (paralysis of accommodation). The drug acts within 15–30 minutes with a duration of 3–8 hours, making it a standard tool in ophthalmologic examination and procedures. Heavily pigmented irides may require higher doses than lightly pigmented ones.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team contraction or strategic repositioning.
Mechanism of Action
CLINICAL PHARMACOLOGY This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). The stronger preparation (1%) also paralyzes accommodation. This preparation acts in 15-30 minutes, and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MYDRIACYL offers stable, operationally focused roles in a mature ophthalmic franchise with strong brand recognition but limited growth prospects. Roles are likely concentrated in commercial defense and maintenance rather than innovation, appealing to professionals seeking stability over expansion.
Brand Manager
Worked on MYDRIACYL at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.